🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Experts discuss results from MARIPOSA-2 and the role of amivantamab + lazertinib + chemotherapy in patients with advanced #NSCLC following progression on osimertinib. Virginia Cancer Specialists Alex Spira, M.D. Oncology Brothers targetedonc.com/view/mariposa-…

Dipiti Patel Donnelly, MD, of Virginia Cancer Specialists joined us to discuss how clinicians can manage high-risk hematologic malignancies in the community. To learn more, visit onclive.com ASH #ASH23 #oncology

A2.1 Because pancreatic cancer is very difficult to treat, patients may want to consider participating in a clinical trial. #PancChat

The MARIPOSA trial of amivantamab + lazertinib vs standard-of-care osimertinib for the treatment of EGFR-mutated #NSCLC had promising results, showing the superiority of amivantamab/lazertinib over osimertinib. Alex Spira, M.D. Virginia Cancer Specialists targetedonc.com/view/amivantam…

A shared neoantigen vaccine combined with immune checkpoint blockade for advanced metastatic solid tumors: phase 1 trial interim results nature.com/articles/s4159… @gritstonebio therapeutic vaccine data in KRAS mutant solid tumors. The overall response rate was 0%! Nature Medicine

I was invited to speak on mgmt of AEs for new #lungcancer EGFR therapies and learned so much more from this great panel of experts Alex Spira, M.D. Sandip Patel MD FASCO

🚨New Paper Alert!🚨 Amivantamab-Lazertinib Improves Outcomes in High-Risk EGFR-Mutant NSCLC Subgroups: MARIPOSA Study Results Annals of Oncology Enriqueta Felip Nicolas Girard Alex Spira, M.D. Raffaele Califano Luis Paz-Ares oncodaily.com/insight/93672.… Summary by Amalya Sargsyan

Study MARIPOSA: FDA approves amivantamab-vmjw + lazertinib as first-line for EGFR+ NSCLC. Superior PFS over osimertinib! New standard of care? bit.ly/3yC9cFl #NSCLC IASLC NEJM Alex Spira, M.D.

Well #WCLC2024 is a wrap! Sandip Patel MD FASCO Narjust Florez, MD, FASCO and their cochairs as well as the IASLC staff - outstanding job! All of the presenters and faculty were stellar! Thx for making this WCLC one to remember!❤️ #IASLC family

An ORR of 74% (95% CI, 48.8%-90.9%) among 19 evaluable patients was observed, with anti-tumor activity occurring across all dose levels. #lcsm | Alex Spira, M.D. cancernetwork.com/view/dll3-targ…

In the MARIPOSA trial, researchers assessed the efficacy and safety of amivantamab–lazertinib, as compared with osimertinib, as first-line treatment in patients with advanced NSCLC with EGFR mutations. Full trial results and Plain Language Summary: nej.md/3zkBeFi

CHRYSALIS-2 Cohort A: amivantamab + lazertinib in #EGFR NSCLC after osimertinib and chemotherapy JTO & JTO CRR (n=162). BICR RR 35%, CBR 58%, DOR 8.3m, PFS 4.5m, OS 14.8m, and CNS efficacy noted. AEs included rash in 81% (G3 10%), paronychia in 52%. jto.org/article/S1556-…

Thank you to Alex Spira, M.D., of Virginia Cancer Specialists, who spoke with us at #GI25 about findings from a phase 1 study of RMC-9805 in pancreatic cancer. Check back on our site to see a clip from this video interview! @asco #pancsm #oncology onclive.com/conference/gi

RAS(ON) Inhibitor Zoldonrasib Is Safe, Shows Early Activity Signals in KRAS G12D–Mutated PDAC Alex Spira, M.D. ASCO #GI25 #pansm #oncology onclive.com/view/ras-on-in…

WATCH: Alex Spira, M.D. of Virginia Cancer Specialists discusses the clinical implications of ctDNA for treatment decisions and monitoring in patients with KRAS G12D pancreatic ductal adenocarcinoma treated with zoldonrasib. #PDAC #GI25 hubs.li/Q034z-rv0

These posters were next to each other. Excitement from ⁦Alex Spira, M.D.⁩ bubbling over ⁦ASCO⁩ #GI25 #revolutionmed #kentbarnes ⁦VirginiaCancer⁩ youtu.be/jFJM1W5bUQA

#AACR25 Preliminary safety and antitumor activity of zoldonrasib (RMC-9805), an oral, RAS(ON) G12D-selective, tri-complex inhibitor in patients with KRAS G12D non-small cell lung cancer (NSCLC) from a phase 1 study in advanced solid tumors

Amivantamab in Participants with Advanced Non-small Cell Lung Cancer (NSCLC) and MET Exon 14 Skipping Mutations: Final Results From the CHRYSALIS Study buff.ly/JIAtTJe Amivantamab, a bispecific EGFR-MET antibody with immune cell-engaging properties, demonstrated

🚨 ASCO Olomorasib + pembrolizumab in 1L advanced KRAS G12C NSCLC shows encouraging efficacy across all PD-L1 levels 🔹 ORR: 74% 🔹 DCR: 91% 🔹 PD-L1 ≥50%: ORR 90%, DCR 95% 🔹 TRAEs mostly hepatic, manageable 🧪 Global Ph3 trial ongoing (SUNRAY-01) Alex Spira, M.D. #ASCO2025

🔄#ASCO25 REVIEW🔁 ☑️#LCSM Rapid Oral, Mets 🔥LOXO-RAS-20001: Olomorasib + immunotherapy in first-line Tx of pts with KRAS G12C-mutant advanced NSCLC 🎙️ Alex Spira, M.D. 🎯Overall ORR 70%, DCR 90% 🎯PD-L1 ≥50% ORR 82%, DCR 94% OncoAlert ASCO LARVOL meetings.asco.org/2025-asco-annu…